Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
Arielle J. Medford(Harvard University), Aditya Bardia(UCLA Health), Beverly Moy(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Andrzej Niemierko(Harvard University), Taronish D. Dubash(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), Neelima Vidula(Harvard University), Benjamin Wesley(Harvard University), Brittany A. Reeves(Harvard University), Leif W. Ellisen(Harvard University), A. John Iafrate(Peter MacCallum Cancer Centre), Joseph A. LiCausi(Harvard University), Ben S. Wittner(Broad Institute), Shyamala Maheswaran(Massachusetts General Hospital), Michael S. Lawrence(Broad Institute), Mehmet Toner(Shriners Hospitals for Children - Erie), Dejan Juric(Massachusetts General Hospital), Giuliana Malvarosa(Harvard University), Steven J. Isakoff(Harvard University), Megan Yuen(Harvard University), Jeffrey Peppercorn(Durham University)
Cited by 30